Evotec stock gains 0.9 percent near its yearly low

Published on 09/23/2026 at 12:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock reached EUR 2.83 on September 23, 2026, while the 52-week range ran from EUR 2.73 to EUR 7.30. Second-quarter revenue fell 16.21 percent.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec SE stock (ISIN DE0005664809) traded at EUR 2.83 on Xetra on September 23, 2026, up 0.9 percent during morning trading. The quotation stood only 3.46 percent above the 52-week low of EUR 2.73 recorded on September 22, while the 52-week high was EUR 7.30 on October 27, 2025.

Stock stays near yearly low

The price structure remains the clearest current signal. Evotec stock was 61.21 percent below its 52-week high on September 23, 2026, while the latest quoted session level was EUR 2.83. Trading volume reached 15,719 shares in the Xetra session cited by Finanzen on September 23, 2026.

The preceding completed Xetra close was EUR 2.79 on September 21, 2026, after a reported decline of 4.12 percent. A session quotation of EUR 2.83 on September 22 represented a 1.4 percent gain, outperforming the DAX by 1.38 percentage points, according to Ad-hoc News on September 23, 2026.

Revenue falls in Q2 2026

The latest reported quarter adds a fundamental counterweight to the modest intraday gain. Evotec reported revenue of EUR 143.48 million for the quarter ended June 30, 2026, down 16.21 percent from EUR 171.24 million in the prior-year quarter, according to Finanzen on September 23, 2026.

Loss per share was EUR 0.26 in the second quarter of 2026, compared with a loss of EUR 0.24 in the same quarter of 2025. The figures show that the share price is trading close to its annual trough while the latest quarterly comparison still records weaker revenue and a wider per-share loss.

Pipeline progress meets caution

A company update cited in current market coverage said the JST-018 antibody entered Phase I and that a Plectonic collaboration targets solid tumors. The same coverage described 2026 guidance as cautious while placing the stock at EUR 2.84 and market capitalization at EUR 517.80 million on September 22, 2026, according to Ad-hoc News.

For investors, the key contrast is quantitative: the stock remained 61.21 percent below its 52-week high, while second-quarter revenue declined 16.21 percent year over year. Pipeline development provides an operating datapoint, but the latest reported revenue comparison keeps execution and guidance central to the valuation discussion.

Evotec stock closes at EUR 2.83

Evotec stock was quoted at EUR 2.83 on Xetra on September 23, 2026, with a 0.9 percent morning gain, a 52-week range of EUR 2.73 to EUR 7.30, and 15,719 shares traded in the cited session.